SCHEMBL3246280

SCHEMBL3246280

CC(=O)ON(C=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ALDH1A1 P00352 4/20 0.37
GLA P06280 2/20 0.37
TDP1 Q9NUW8 3/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ELANE P08246 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ESR1 P03372 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
HMGB1 P09429 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245009 0.83 NPSR1 (0.38) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL2775700 0.81 LMNA (0.35) TSHRMEN1KMT2AALDH1A1TDP1
SCHEMBL4467640 0.75 NPSR1 (0.44) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL9297162 0.75 NPSR1 (0.44) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL1335025 0.75 KMT2A (0.38) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL28217153 0.74 NPSR1 (0.43) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL28001086 0.74 ALDH1A1 (0.45) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL3279596 0.72 NPSR1 (0.41) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL11454677 0.72 ALDH1A1 (0.44) TSHRMEN1KMT2ANPSR1ALDH1A1
SCHEMBL28750160 0.72 ALDH1A1 (0.44) TSHRMEN1KMT2ANPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 TSHR 2306/4885MEN1 300/4885KMT2A 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.